Toxicité endobuccale des thérapies ciblées anticancéreuses

Sibaud, Vincent; Boralévi, F.; Vigarios, Émmanuelle; Fricain, Jean-Christophe

doi:10.1016/j.annder.2014.03.009

Cited by 17 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral lichenoid reactions are frequently observed in patients treated with the first-generation BCR-ABL tyrosine kinase inhibitor (TKI) imatinib and are characterized by a combination of reticular striae with symptomatic ulcerative, erosive, or atrophic lesions [ 53 ]. Often underestimated, these lesions can be isolated or associated with nail or skin reactions and regular follow-up is recommended.…”

Section: Oral Mucosal Toxicitiesmentioning

confidence: 99%

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

2018

View full text Add to dashboard Cite

Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25–85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. BRAF inhibitors mostly induce secondary skin tumors, squamous cell carcinoma and keratoacanthomas, changes in pre-existing pigmented lesions, as well as hand-foot skin reactions and maculopapular hypersensitivity-like rash. Immune checkpoint inhibitors (ICIs) most frequently induce nonspecific maculopapular rash, but also eczema-like or psoriatic lesions, lichenoid dermatitis, xerosis, and pruritus. Of the oral mucosal toxicities observed with targeted therapies, oral mucositis is the most frequent with mammalian target of rapamycin (mTOR) inhibitors, followed by stomatitis associated to multikinase angiogenesis and HER inhibitors, geographic tongue, oral hyperkeratotic lesions, lichenoid reactions, and hyperpigmentation. ICIs typically induce oral lichenoid reactions and xerostomia. Targeted therapies and endocrine therapy also commonly induce alopecia, although this is still underreported with the latter. Finally, targeted therapies may damage nail folds, with paronychia and periungual pyogenic granuloma distinct from chemotherapy-induced lesions. Mild onycholysis, brittle nails, and a slower nail growth rate may also be observed. Targeted therapies and immunotherapies often profoundly diminish patients’ quality of life, which impacts treatment outcomes. Close collaboration between dermatologists and oncologists is therefore essential.

show abstract

Section: Oral Mucosal Toxicitiesmentioning

confidence: 99%

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

2018

View full text Add to dashboard Cite

show abstract

“…The stomatitis caused by this kind of targeted therapy presents as a diffuse mucosal hypersensitivity/dysesthesia which can be associated with moderate erythema or inflammation of the oral mucosa. The symptoms appear in the first week of treatment and then gradually disappear [ 67 , 89 ]. The literature reports that sunitinib and sorafenib may cause linear lingual ulcers of the nonkeratinized mucosa.…”

Section: Discussionmentioning

confidence: 99%

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Arena

Troiano

Lillo

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Background Multitargeted tyrosine kinase inhibitors (TKIs) represent a new class of target-specific antineoplastic agents. These agents show some specific adverse events such as fatigue/asthenia, anorexia/loss of appetite, dysgeusia, diarrhea/abdominal pain, hypothyroidism, hypertension, myelosuppression, and stomatitis. Materials and Methods A systematic search was performed on PubMed online database using a combination of MESH terms and free text words, “sunitinib” OR “sorafenib” OR “axitinib” OR “cabozantinib” OR “pazopanib” OR “regorafenib” OR “nintedanib” OR “vatalanib” combined through the use of Boolean operator AND with the key words “stomatitis” OR “mucositis,” (i) on human subjects, (ii) written in the English language, and (iii) reporting about the incidence of stomatitis or oral mucositis. Results The incidence of stomatitis of any grade was 35.2% for sunitinib, 20.52% for sorafenib, 20.63% for axitinib, and 34.21% for cabozantinib. All the agents showed high rates of low-grade stomatitis (G1-G2), while the onset of severe stomatitis (G3-G4) was very low. Conclusions Analysis of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4.

show abstract

“…Le diagnostic différentiel doit se faire avec une [9,15,16]. Aucun traitement ne semble indiqué [17]. Aucune évolution péjora-tive n'a été rapportée [2].…”

Section: Discussionunclassified

Pigmentation palatine associée à un traitement par imatinib

Campana¹,

Ordioni²

2014

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Toxicité endobuccale des thérapies ciblées anticancéreuses

Cited by 17 publications

References 64 publications

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails

Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Pigmentation palatine associée à un traitement par imatinib

Contact Info

Product

Resources

About